Physician profile
David B Maybee
NPI 1245286467
$15,337.86
in general payments reported to CMS, 2019-2025
79 companies · $4,895 in 2025
The $4,895 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $1,232 · 2021: $1,648 · 2022: $1,492 · 2023: $2,836 · 2024: $1,528 · 2025: $4,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,534 · Travel and Lodging: $3,533 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.01 |
| Travel and Lodging | $3,532.90 |
| Education | $192.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $2,571.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,491.89 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,272.86 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Inspire Medical Systems, INC. | $1,247.67 | 2023-2025 | Inspire |
| Insmed, INC. | $825.09 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $747.85 | 2019-2024 | Xolair, Actemra, Ocrevus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.65 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $652.01 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Genzyme Corporation | $610.34 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $447.91 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $330.70 | 2019-2025 | Tezspire |
| United Therapeutics Corporation | $312.70 | 2021-2025 | Tyvaso, Tyvaso |
| Janssen Biotech, INC. | $280.18 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $246.63 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $228.69 | 2019-2025 | Zerbaxa, Keytruda, Winrevair |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $171.26 | 2020-2024 | Vyepti |
| Pfizer INC. | $148.92 | 2019-2025 | |
| Akcea Therapeutics, INC. | $143.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.40 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $131.93 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $125.66 | 2023-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $117.73 | 2020-2024 | Ultomiris |
| Csl Behring | $115.32 | 2019-2023 | Kcentra |
| Novo Nordisk INC | $104.28 | 2019-2024 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $102.33 | 2021-2024 | Veklury |
| Teva Pharmaceuticals USA, INC. | $100.97 | 2022-2023 | Austedo Xr, Ajovy, Austedo |
| Sanofi-Aventis U.S. LLC | $98.35 | 2021-2024 | |
| Lilly USA, LLC | $96.24 | 2022-2024 | Mounjaro, Zepbound |
| Banner Life Sciences, LLC | $88.55 | 2023-2024 | |
| Verona Pharma, INC. | $87.04 | 2025 | Ohtuvayre |
| Ethicon INC. | $84.38 | 2024 | Monarch Platform |
| Daiichi Sankyo INC. | $83.52 | 2019-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $81.82 | 2021-2025 | Glassia |
| Sunovion Pharmaceuticals INC. | $73.54 | 2019-2020 | |
| Emd Serono, INC. | $67.03 | 2022-2023 | Mavenclad |
| Amarin Pharma, INC. | $65.36 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $61.76 | 2025 | Alvesco |
| Janssen Pharmaceuticals, INC | $56.93 | 2021-2022 | |
| Philips North America LLC | $56.36 | 2019-2024 | (Ak6) Vest Therapy |
| Viatris Specialty LLC | $51.54 | 2025 | Yupelri |
| Vifor Pharma, INC. | $50.56 | 2024 | Zemaira |
| Biohaven Pharmaceuticals, INC. | $49.99 | 2021 | |
| Medtronic, INC. | $48.58 | 2021-2022 | |
| Mylan Specialty L.P. | $46.70 | 2022 | |
| Argenx US, INC. | $42.95 | 2023 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.90 | 2022 | |
| Baxter Healthcare | $36.63 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Carnation Ambulatory Monitor |
| Harmony Biosciences LLC | $35.14 | 2020-2024 | |
| Allergan, INC. | $33.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $32.17 | 2020-2021 | |
| Kyowa Kirin, INC. | $29.17 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $27.54 | 2022 | |
| Radius Health, INC. | $27.10 | 2024 | Tymlos |
| Jazz Pharmaceuticals INC. | $26.60 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $25.89 | 2019 | |
| Amneal Pharmaceuticals LLC | $24.27 | 2021 | |
| Abbvie INC. | $24.20 | 2021 | |
| Corium, LLC | $23.97 | 2022 | |
| Ucb, INC. | $23.60 | 2023 | Cimzia |
| Sandoz INC. | $23.01 | 2023 | Hyrimoz |
| Esperion Therapeutics, INC. | $21.05 | 2021 | |
| Neurocrine Biosciences, INC. | $20.12 | 2023 | Ongentys, Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $19.55 | 2021 | |
| Boston Scientific Corporation | $19.39 | 2019 | |
| Eisai INC. | $19.21 | 2023 | |
| Avanir Pharmaceuticals, INC. | $18.16 | 2022 | |
| Circassia INC. | $16.79 | 2019 | |
| Pulmonx Corporation | $16.20 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Vertical Pharmaceuticals, LLC | $15.83 | 2020 | |
| Axsome Therapeutics, INC. | $15.19 | 2025 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2021 | |
| Tanabe Pharma America, INC. | $14.51 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.47 | 2023 | Monoferric |
| Inogen, INC. | $14.47 | 2025 | |
| Sk Life Science, INC. | $13.33 | 2022 | |
| Veran Medical Technologies, INC. | $12.98 | 2021 | |
| Advanced Respiratory, INC | $12.36 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maybee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.